Montarello, Nicholas J.
Singh, Kuljit
Sinhal, Ajay
Wong, Dennis T. L.
Alcock, Richard
Rajendran, Sharmalar
Dautov, Rustem
Barlis, Peter
Patel, Sanjay
Nidorf, Stefan M.
Thompson, Peter L.
Salagaras, Thalia
Butters, Julie
Nerlekar, Nitesh
Di Giovanni, Giuseppe
Ottaway, Juanita L.
Nicholls, Stephen J.
Psaltis, Peter J.
Funding for this research was provided by:
national health and medical research council (ID 1127159, ID 1111630, CDF 1161506)
national heart foundation of australia (Vanguard Grant ID 10137, FLF 102535, FLF 102056)
sylvia and charles viertel charitable foundation (VIERCI 2017016)
Article History
Accepted: 13 August 2021
First Online: 25 August 2021
Declarations
:
: All procedures in this study will be conducted in accordance with the Declaration of Helsinki, International Conference on Harmonization, Good Clinical Practice guidelines and applicable regulatory requirements. The final protocol and informed consent forms were approved by the Royal Adelaide Hospital Human Research Ethics Committee (HREC) under the National Mutual Acceptance (NMA) system with local Research Governance Officer (RGO) approval at each site (HREC/17/RAH/366; Central Adelaide Local Health Network Reference Number R20170904). This clinical trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12618000809235). Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: K.S. has received research support and consultant fees from Abbott Vascular and Bayer. A.S. has received consultant fees and speaker honoraria from Edwards Lifesciences, Medtronic, Boston Scientific, AstraZeneca and Abbott Vascular. D.T.L.W. has received speaker honoraria from AstraZeneca, Pfizer, Bayer and Boehringer Ingelheim. P.L.T. has received research grants or honoraria from Amarin, Amgen, Aspen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, DalCor, Merck and Pfizer. S.J.N. has received research support from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and Liposcience and is a consultant for AstraZeneca, Akcea, Eli Lilly, Anthera, Kowa, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion and Boehringer Ingelheim. P.J.P. has received research support from Abbott Vascular, consulting fees from Amgen and Esperion and speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Schering-Plough and Pfizer.
Free to read: This content has been made available to all.